Considering the cost-effectiveness of statins in family practice in Turkey from a payer perspective英文文献资料.docVIP

Vol.1, No.4, 274-280 (2009) Health doi:10.4236/health.2009.14044 Considering the cost-effectiveness of statins in family practice in Turkey from a payer perspective Güven? Ko?kaya , Albert Wertheimer , P?nar Daylan Ko?kaya , Ahmet Esen 1 2 3 1 1 2 3 Yeditepe Universitesi PEPI, Istanbul, Turkey Temple University, School of Pharmacy, Philadelphia, USA ?i?li Etfal Education and Research Hospital, Anesthesia Clinic, Istanbul, Turkey Received 2 October 2009; revised 9 November 2009; accepted 10 November 2009. ABSTRACT age of total cholesterol levels above 200 mg/dL and 249 mg/dL were 25% and 5% respectively [1]. The percentage of mortality caused by cardio- vascular events in European Countries and European Union Countries is respectively 49% and 42% of all mortality causes. Our estimates about cardiovascular mortality in Turkey depend on TEKHARF (Hearth Disease and Risk Factors in Turkish Adults) which depended on a 12 year observation. It has been reported that cardio- vascular mortality rates for Turkey in men and women were 0.082% and 0.043% respectively. In Turkey, Atorvastatin, Fluvastatin, Pravastatin, Rosuvastatin and Simvastatin are the different alternatives found in the statin market. All stat- ins are reimbursed by insurance companies. The aim of this study is to determine the cost- effectiveness of statins. In conclusion, simvas- tatin and rosuvastatin comprised the optimal two statin alternatives. LDL decreasing and HDL increasing can decrease cardiovascular events. Statins can decrease LDL and increase HDL [2-8]. Some benefits in cardiovascular event protection statin use is increasing [9,10]. In Turkey, there is Atorvastatin, Fluvastatin, Pravas- tatin, Rosuvastatin and Simvastatin in the statin market. And all statins a